ResveratrolvsRetinyl Palmitate

Resveratrol activates SIRT1 (sirtuin 1), a NAD+-dependent deacetylase that deacetylates histones and non-histone targets including p53, FOXO transcription factors, and NF-κB, regulating cellular stress response, DNA repair, autophagy, and inflammatory pathways in keratinocytes and fibroblasts. It scavenges superoxide anion, hydroxyl radical, and metal-induced free radicals through its phenolic hydroxyl groups. Resveratrol inhibits NF-κB nuclear translocation and downstream cytokine production (TNF-α, IL-1β, IL-6), reducing UV-induced inflammation. It inhibits tyrosinase (mild brightening), matrix metalloproteinase-9 (MMP-9, gelatinase B) to prevent collagen and elastin breakdown, and AP-1 (c-Fos/c-Jun) to reduce photoaging-related gene expression. It may also activate Nrf2, upregulating antioxidant enzymes (HO-1, NQO1). Topical application achieves higher skin tissue concentrations than oral supplementation due to first-pass metabolism. Stability is improved in anhydrous or encapsulated formulations.

Retinyl palmitate is cleaved by cutaneous esterases (including retinyl ester hydrolase) to release retinol, which then undergoes oxidation by retinol dehydrogenase to retinaldehyde, followed by RALDH conversion to retinoic acid. The three-step enzymatic cascade means very little active retinoic acid reaches nuclear RAR receptors at any given time, explaining the low potency and minimal retinization. The palmitate ester bond provides exceptional stability — resistant to UV-induced isomerization and oxidative degradation that affects retinol. This slow-release profile makes it suitable for sensitive skin and daytime use. The limited retinoic acid flux still provides mild stimulation of collagen type I synthesis and epidermal turnover, though clinical effects are subtle compared to stronger retinoids.